144 related articles for article (PubMed ID: 19112514)
1. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.
Mendiola M; Barriuso J; Redondo A; Mariño-Enríquez A; Madero R; Espinosa E; Vara JA; Sánchez-Navarro I; Hernández-Cortes G; Zamora P; Pérez-Fernández E; Miguel-Martín M; Suárez A; Palacios J; González-Barón M; Hardisson D
PLoS One; 2008; 3(12):e4051. PubMed ID: 19112514
[TBL] [Abstract][Full Text] [Related]
2. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
Yoshihara K; Tajima A; Yahata T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Kotera K; Masuzaki H; Tashiro H; Katabuchi H; Inoue I; Tanaka K
PLoS One; 2010 Mar; 5(3):e9615. PubMed ID: 20300634
[TBL] [Abstract][Full Text] [Related]
4. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
5. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Rossi E; Donzelli C; Todeschini P; Romani C; Bandiera E; Zanotti L; Carnazza M; Quadraro F; Tognon G; Sartori E; Pecorelli S; Roque DM; Santin AD
J Transl Med; 2013 Jul; 11():162. PubMed ID: 23819652
[TBL] [Abstract][Full Text] [Related]
6. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
7. Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
Spentzos D; Levine DA; Kolia S; Otu H; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2005 Nov; 23(31):7911-8. PubMed ID: 16204010
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study.
Daponte A; Ioannou M; Mylonis I; Simos G; Minas M; Messinis IE; Koukoulis G
BMC Cancer; 2008 Nov; 8():335. PubMed ID: 19014607
[TBL] [Abstract][Full Text] [Related]
9. A seven-gene prognostic model for platinum-treated ovarian carcinomas.
Sabatier R; Finetti P; Bonensea J; Jacquemier J; Adelaide J; Lambaudie E; Viens P; Birnbaum D; Bertucci F
Br J Cancer; 2011 Jul; 105(2):304-11. PubMed ID: 21654678
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and ovarian cancer.
Gómez-Raposo C; Mendiola M; Barriuso J; Casado E; Hardisson D; Redondo A
Clin Transl Oncol; 2009 Sep; 11(9):564-71. PubMed ID: 19775995
[TBL] [Abstract][Full Text] [Related]
11. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
Taskiran C; Erdem O; Onan A; Arisoy O; Acar A; Vural C; Erdem M; Ataoglu O; Guner H
Int J Gynecol Cancer; 2006; 16(5):1789-93. PubMed ID: 17009973
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK
J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
16. A prognostic gene expression index in ovarian cancer - validation across different independent data sets.
Denkert C; Budczies J; Darb-Esfahani S; Györffy B; Sehouli J; Könsgen D; Zeillinger R; Weichert W; Noske A; Buckendahl AC; Müller BM; Dietel M; Lage H
J Pathol; 2009 Jun; 218(2):273-80. PubMed ID: 19294737
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
18. Dicer, Drosha, and outcomes in patients with ovarian cancer.
Merritt WM; Lin YG; Han LY; Kamat AA; Spannuth WA; Schmandt R; Urbauer D; Pennacchio LA; Cheng JF; Nick AM; Deavers MT; Mourad-Zeidan A; Wang H; Mueller P; Lenburg ME; Gray JW; Mok S; Birrer MJ; Lopez-Berestein G; Coleman RL; Bar-Eli M; Sood AK
N Engl J Med; 2008 Dec; 359(25):2641-50. PubMed ID: 19092150
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.
Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR
Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144
[TBL] [Abstract][Full Text] [Related]
20. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
